Developing the best MATCH for patients through plug & play assembly of novel multispecific biotherapeutics.

Advancing a proprietary pipeline of next generation immunology and immuno-oncology drugs.

Establishing leading platform of next generation plug & play novel multispecific therapeutics.

News

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis Read more

Pipeline

Read more about our
progress here
numab graphic numab graphic numab graphic numab graphic

Overcoming limitations of existing approaches to uncover vast potential for new medicines

Our proprietary platforms λ-Cap™ and MATCH™ are designed to create differentiated therapeutics on a repeatable basis. Using a novel, rational process, our discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Spearheading the development of first- and best-in-class high-impact therapeutics

We use validated discovery and engineering technologies to improve the predictability of the drug discovery process. We are establishing a proprietary pipeline of highly differentiated therapeutics by targeting clinically validated pathways with multispecific molecules to create novel mechanisms of action designed to overcome the limitations of existing approaches and differentiate from standard of care by superior efficacy and favorable safety.

Advancing our lead program NM26, a bispecific antibody targeting IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis and other type 2 inflammatory disorders

NM26-2198 is designed to prevent IL-4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis (AD). The targeting of the IL-4/IL-13 pathway is well established for the treatment of AD and other inflammatory diseases. We believe that adding IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade could enable a faster onset of action and improved efficacy compared to the current standard of care in AD, together with convenient subcutaneous administration. Atopic Dermatitis still has a high unmet medical need and represents a multi-billion-dollar market opportunity. Numab develops this program together with Kaken Pharmaceutical Co., Ltd, our regional partner in Japan.

Latest News

May 28, 2024 Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications.
Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights.
NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using its proprietary MATCH™ technology platform.

Download PDF
February 14, 2024 Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer

NM49 is a multi-specific antibody identified through Numab’s proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosis.
Numab to receive upfront payment and eligible to receive additional milestone payments plus option to co-develop with profit split arrangement in the United States.
Agreement marks third collaboration agreement between Numab and Ono Pharmaceutical.

Download PDF
October 19, 2023 Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis

NM26 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets,
targeting the underlying inflammation as well as the neuroinflammatory pathway that causes itch.

Download PDF

Stay informed.

Cookies: OK! Privacy Statement